← Eichor
Condition: Primary Peritoneal Carcinoma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Primary Peritoneal Carcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Pr
Phase 1/Phase 2 · 4 location(s) · Imunon · NCT05739981Nab-paclitaxel Versus Sb-taxanes As First-Line Treatment in Advanced Ovarian Cancer
Phase 3 · 11 location(s) · Women's Hospital School Of Medicine Zhejiang University · NCT05737303Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemo
Phase 3 · 8 location(s) · Imunon · NCT06915025Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Phase 1/Phase 2 · 13 location(s) · Exscientia AI Ltd., a wholly owned subsidiary of Recursion P · NCT05985655MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)
Phase 3 · 53 location(s) · Swiss GO Trial Group · NCT04111978A Study of Lorigerlimab in Participants With Advanced Solid Tumors
Phase 2 · 16 location(s) · MacroGenics · NCT06730347Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Beva
Phase 3 · 32 location(s) · Genelux Corporation · NCT05281471Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers
Phase 1 · 2 location(s) · M.D. Anderson Cancer Center · NCT03968406Characterization of Epithelial Ovarian Cancer Patients in Terms of Homologous Recombination Phenotype
Phase N/A · 1 location(s) · Nordic Society of Gynaecological Oncology - Clinical Trials · NCT05574673Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers, CHANCES Study
Phase N/A · 1 location(s) · University of Washington · NCT06295965ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer
Phase 2 · 2 location(s) · Ira Winer · NCT04055649A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combinatio
Phase 1 · 5 location(s) · Regeneron Pharmaceuticals · NCT06469281Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07480954Study of CryptiVax-1001 in Maintenance Setting for Advanced Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase 1 · 10 location(s) · Epitopea Ltd · NCT07665515HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer
Phase 2 · 28 location(s) · Hansoh BioMedical R&D Company · NCT06014190An Automated Personalized Physical Activity Intervention to Improve Immune Function and Clinical Outcomes in Stage II-IV
NA · 1 location(s) · Roswell Park Cancer Institute · NCT06855706A Study of Maintenance DCVAC/OvCa After First-line Chemotherapy Added Standard of Care
Phase 2 · 1 location(s) · Peking University Third Hospital · NCT04834544A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.
Phase 2 · 17 location(s) · Shanghai Jiaolian Drug Research and Development Co., Ltd · NCT06434610Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Phase 2 · 54 location(s) · Regeneron Pharmaceuticals · NCT06787612Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Phase 1/Phase 2 · 66 location(s) · Genmab · NCT05579366Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel i
Phase 1 · 1 location(s) · M.D. Anderson Cancer Center · NCT05092373A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
Phase 1 · 17 location(s) · NextCure, Inc. · NCT06792552Registry Platform Ovarian and Endometrial Cancer
Phase N/A · 1 location(s) · iOMEDICO AG · NCT05129969A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent
Phase 3 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT06994195Data Collection for Patients With Low Grade Ovarian or Peritoneal Tumors
Phase N/A · 1 location(s) · M.D. Anderson Cancer Center · NCT00488878The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr
Phase 2 · 1 location(s) · Mayo Clinic · NCT07285044Survival Effect of Hepato-celiac Lymphadenectomy In Primary or Relapsed Ovarian Cancer
NA · 1 location(s) · Shanghai Gynecologic Oncology Group · NCT05236686A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Gr
Phase 2 · 52 location(s) · AbbVie · NCT06682988Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Re
Phase 2 · 2 location(s) · Roswell Park Cancer Institute · NCT05231122CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
Phase 2 · 66 location(s) · TORL Biotherapeutics, LLC · NCT06690775
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.